TRINQUIS Trademark

Trademark Overview


On Wednesday, April 19, 2023, a trademark application was filed for TRINQUIS with the United States Patent and Trademark Office. The USPTO has given the TRINQUIS trademark a serial number of 97896222. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, September 24, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The TRINQUIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications. Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for us...
trinquis

General Information


Serial Number97896222
Word MarkTRINQUIS
Filing DateWednesday, April 19, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, September 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 6, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications. Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
Translation of Words in MarkThe wording "TRINQUIS" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Wednesday, January 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, April 22, 2023NEW APPLICATION ENTERED
Monday, May 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 2, 2024ASSIGNED TO EXAMINER
Wednesday, January 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 6, 2024PUBLISHED FOR OPPOSITION
Tuesday, February 6, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 24, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, September 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2024SOU EXTENSION 1 GRANTED
Tuesday, September 24, 2024SOU EXTENSION 1 FILED